300158 振东制药
已收盘 05-29 15:00:00
资讯
新帖
简况
振东制药(300158)披露股东股份质押公告,5月28日股价上涨0.81%
证券之星 · 05-28 17:34
振东制药(300158)披露股东股份质押公告,5月28日股价上涨0.81%
振东制药(300158)披露将参加山西辖区上市公司2026年投资者网上集体接待日暨年报业绩说明会,5月19日股价上涨2.33%
证券之星 · 05-19
振东制药(300158)披露将参加山西辖区上市公司2026年投资者网上集体接待日暨年报业绩说明会,5月19日股价上涨2.33%
振东制药(300158)披露2025年年度股东会决议公告,5月15日股价下跌0.87%
证券之星 · 05-15
振东制药(300158)披露2025年年度股东会决议公告,5月15日股价下跌0.87%
振东制药:公司治理架构稳定规范
证券之星 · 05-13
振东制药:公司治理架构稳定规范
振东制药:参与公司员工持股计划的员工对公司长期价值及未来发展高度认可
证券之星 · 05-13
振东制药:参与公司员工持股计划的员工对公司长期价值及未来发展高度认可
振东制药(300158)披露第四期员工持股计划完成股票购买公告,5月7日股价下跌2.16%
证券之星 · 05-07
振东制药(300158)披露第四期员工持股计划完成股票购买公告,5月7日股价下跌2.16%
振东制药(300158)披露第五期员工持股计划第一次持有人会议决议公告,5月6日股价上涨5.07%
证券之星 · 05-06
振东制药(300158)披露第五期员工持股计划第一次持有人会议决议公告,5月6日股价上涨5.07%
振东制药:一季度营收6.49亿元 经营现金流同比增长7.86%
中国财富通 · 04-24
振东制药:一季度营收6.49亿元 经营现金流同比增长7.86%
振东制药:公司于每月末公布员工持股进展
证券之星 · 04-23
振东制药:公司于每月末公布员工持股进展
振东制药:公司相关销售均基于真实业务背景,收入真实合规
证券之星 · 04-23
振东制药:公司相关销售均基于真实业务背景,收入真实合规
股市必读:振东制药年报 - 第四季度单季净利润同比增长76.52%
证券之星 · 04-22
股市必读:振东制药年报 - 第四季度单季净利润同比增长76.52%
图解振东制药年报:第四季度单季净利润同比增长76.52%
证券之星 · 04-21
图解振东制药年报:第四季度单季净利润同比增长76.52%
振东制药(300158.SZ)发布一季度业绩,由盈转亏至104.59万元
智通财经 · 04-20
振东制药(300158.SZ)发布一季度业绩,由盈转亏至104.59万元
振东制药(300158)披露为全资子公司提供担保进展公告,4月3日股价下跌4.64%
证券之星 · 04-03
振东制药(300158)披露为全资子公司提供担保进展公告,4月3日股价下跌4.64%
振东制药(300158)披露第四期员工持股计划第一次持有人会议决议公告,1月30日股价下跌2.56%
证券之星 · 01-30
振东制药(300158)披露第四期员工持股计划第一次持有人会议决议公告,1月30日股价下跌2.56%
振东制药:1月26日高管雷振宏增持股份合计1600股
证券之星 · 01-27
振东制药:1月26日高管雷振宏增持股份合计1600股
股市必读:振东制药(300158)预计2025年全年归属净利润亏损2.2亿元至2.8亿元
证券之星 · 01-26
股市必读:振东制药(300158)预计2025年全年归属净利润亏损2.2亿元至2.8亿元
振东制药(300158.SZ)发预亏,预计2025年归母净亏损2.2亿元至2.8亿元
智通财经网 · 01-23
振东制药(300158.SZ)发预亏,预计2025年归母净亏损2.2亿元至2.8亿元
每周股票复盘:振东制药(300158)聘任王锐为新任总裁
证券之星 · 01-03
每周股票复盘:振东制药(300158)聘任王锐为新任总裁
振东制药(300158)披露副总裁、董事会秘书辞职暨聘任总裁公告,12月31日股价上涨0.35%
证券之星 · 2025-12-31
振东制药(300158)披露副总裁、董事会秘书辞职暨聘任总裁公告,12月31日股价上涨0.35%
加载更多
公司概况
公司名称:
山西振东制药股份有限公司
所属行业:
医药制造业
上市日期:
2011-01-07
主营业务:
山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是复方苦参注射液、米诺地尔搽剂、生白颗粒、舒血宁注射液、西黄丸、独一味颗粒、复方胰酶散、大山楂丸。公司荣获“全国先进基层党组织”“全国脱贫攻坚先进集体”两个荣誉称号,荣获“第七届百姓安全用药”放心药奖、“山西省著名商标”等荣誉。
发行价格:
38.80
{"stockData":{"symbol":"300158","market":"SZ","secType":"STK","nameCN":"振东制药","latestPrice":5.03,"timestamp":1780038219000,"preClose":4.99,"halted":0,"volume":14276514,"delay":0,"changeRate":0.008,"floatShares":991000000,"shares":992000000,"eps":-0.3057,"marketStatus":"已收盘","change":0.04,"latestTime":"05-29 15:00:00","open":5,"high":5.08,"low":4.96,"amount":71603300,"amplitude":0.024,"askPrice":5.04,"askSize":1527,"bidPrice":5.03,"bidSize":373,"shortable":0,"etf":0,"ttmEps":-0.3057,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1780277400000},"marketStatusCode":5,"adr":0,"adjPreClose":4.99,"symbolType":"stock","openAndCloseTimeList":[[1780018200000,1780025400000],[1780030800000,1780038000000]],"highLimit":5.49,"lowLimit":4.49,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":992303056,"isCdr":false,"pbRate":1.48,"roa":"--","roe":"--","epsLYR":-0.2998,"committee":-0.443674,"marketValue":4991000000,"turnoverRate":0.0144,"status":0,"floatMarketCap":4987000000},"requestUrl":"/m/hq/s/300158","defaultTab":"news","newsList":[{"id":"2638616466","title":"振东制药(300158)披露股东股份质押公告,5月28日股价上涨0.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638616466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2638616466?lang=zh_cn&edition=full","pubTime":"2026-05-28 17:34","pubTimestamp":1779960873,"startTime":"0","endTime":"0","summary":"截至2026年5月28日收盘,振东制药报收于4.99元,较前一交易日上涨0.81%,最新总市值为49.52亿元。近日,振东制药发布《关于股东股份质押的公告》。公告显示,公司控股股东山西振东健康产业集团有限公司将其持有的11,200,000股公司股份质押给中国银行股份有限公司长治市分行,占其所持股份比例3.71%,占公司总股本比例1.13%,质押用途为自身生产经营。本次质押后,振东集团累计质押股份143,800,000股,占其所持股份比例47.58%,占公司总股本比例14.49%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800031612.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0060","BK0186","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636832871","title":"振东制药(300158)披露将参加山西辖区上市公司2026年投资者网上集体接待日暨年报业绩说明会,5月19日股价上涨2.33%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636832871","media":"证券之星","labels":["conferences"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636832871?lang=zh_cn&edition=full","pubTime":"2026-05-19 17:40","pubTimestamp":1779183649,"startTime":"0","endTime":"0","summary":"截至2026年5月19日收盘,振东制药报收于5.7元,较前一交易日上涨2.33%,最新总市值为56.56亿元。该股当日开盘5.57元,最高5.71元,最低5.55元,成交额达4626.33万元,换手率为0.83%。近日,振东制药发布《关于参加山西辖区上市公司2026年投资者网上集体接待日暨年报业绩说明会活动的公告》。投资者可于5月22日12:00前通过公司指定邮箱提交问题。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051900034002.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635088933","title":"振东制药(300158)披露2025年年度股东会决议公告,5月15日股价下跌0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2635088933","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635088933?lang=zh_cn&edition=full","pubTime":"2026-05-15 17:59","pubTimestamp":1778839152,"startTime":"0","endTime":"0","summary":"截至2026年5月15日收盘,振东制药报收于5.7元,较前一交易日下跌0.87%,最新总市值为56.56亿元。该股当日开盘5.73元,最高5.77元,最低5.68元,成交额达4682.06万元,换手率为0.83%。振东制药于近日披露《2025年年度股东会决议公告》。会议由董事会召集,董事长李昆主持,出席股东及股东代表共300人,代表股份占公司有表决权总股份的31.0737%。表决程序合法有效,北京大成律师事务所出具了法律意见书。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051500034676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787506","title":"振东制药:公司治理架构稳定规范","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787506","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635787506?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:53","pubTimestamp":1778676808,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药05月13日在投资者关系平台上答复投资者关心的问题。投资者提问:董秘您好:振东制药连续亏损、股价暴跌,请问:1. 管理层履职不力,是否应问责?公司治理架构稳定规范,公司管理层始终勤勉履职、合规经营,持续推进降本增效与业务优化,经营面稳步改善,严格依规开展履职考核管理。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300042543.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0060","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635787540","title":"振东制药:参与公司员工持股计划的员工对公司长期价值及未来发展高度认可","url":"https://stock-news.laohu8.com/highlight/detail?id=2635787540","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2635787540?lang=zh_cn&edition=full","pubTime":"2026-05-13 20:52","pubTimestamp":1778676772,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药05月12日在投资者关系平台上答复投资者关心的问题。观察到公司第四期员工持股计划,不管是持股数量还是投入规模,都明显高于前三期,呈现逐期加大投入的态势。主要规模化种植的中药材品种分别是哪些?公司实施的员工持股计划遵循员工自愿参与的原则,参与公司员工持股计划的员工对公司长期价值及未来发展高度认可。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051300042496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","BK0239","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633126021","title":"振东制药(300158)披露第四期员工持股计划完成股票购买公告,5月7日股价下跌2.16%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633126021","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633126021?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:54","pubTimestamp":1778165654,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘,振东制药报收于5.88元,较前一交易日下跌2.16%,最新总市值为58.35亿元。公司于近日披露《关于第四期员工持股计划完成股票购买的公告》。公告显示,山西振东制药股份有限公司第四期员工持股计划已通过二级市场以集中竞价交易方式累计买入公司股票41,408,448股,占公司总股本的4.1730%,成交总金额为243,001,652.48元,成交均价约为5.8684元/股。持股计划实际认购份额未超过股东大会审议通过的拟认购份额上限。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041689.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0239","BK0060","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633813127","title":"振东制药(300158)披露第五期员工持股计划第一次持有人会议决议公告,5月6日股价上涨5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633813127","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633813127?lang=zh_cn&edition=full","pubTime":"2026-05-06 22:20","pubTimestamp":1778077227,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘,振东制药报收于6.01元,较前一交易日上涨5.07%,最新总市值为59.64亿元。振东制药于近日披露《第五期员工持股计划第一次持有人会议决议公告》。公告显示,公司于2026年5月1日召开第五期员工持股计划第一次持有人会议,会议应出席持有人23人,实际参与表决23人,代表本期员工持股计划份额35,490,000份,占总额的64.36%。会议同时授权管理委员会办理员工持股计划的日常管理、份额认购、权益分配、签署协议等相关事宜。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600039761.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0186","BK0239","300158","BK0060"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629963468","title":"振东制药:一季度营收6.49亿元 经营现金流同比增长7.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629963468","media":"中国财富通","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629963468?lang=zh_cn&edition=full","pubTime":"2026-04-24 11:06","pubTimestamp":1777000007,"startTime":"0","endTime":"0","summary":"报告期内,公司实现营业收入6.49亿元,归属于上市公司股东的净利润为-104.59万元,经营现金流同比增长7.86%。2025年报披露,振东制药持续优化经营管理体系、严控各项成本费用,叠加主动收缩非核心亏损业务带来的减亏效应,经营状况呈现稳步向好态势。同时,公司筹资活动现金流净额为1.49亿元,同比增长471.91%,原因为“报告期内取得借款所致”。报告期内,营业外支出为125.93万元,同比减少79.67%,主要原因是“公益性捐赠支出减少”。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://irb.cfbond.com/api/v1/detail.html?newsid=VAldAZ0oXik%3D","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159399","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629834108","title":"振东制药:公司于每月末公布员工持股进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2629834108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629834108?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:52","pubTimestamp":1776948727,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药04月22日在投资者关系平台上答复投资者关心的问题。另外根据深圳证券交易所上市公司信息披露第4号文件员工持股计划中第三章提到的:12月18日,员工持股股东大会通过后必须每个月公告进展!你们公司到2026年1月25号还未见披露,是不是违规了!公司于每月末公布员工持股进展,请关注公司每月末发布的《关于第四期员工持股计划实施进展的公告》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300059140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0060","BK0186","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629834641","title":"振东制药:公司相关销售均基于真实业务背景,收入真实合规","url":"https://stock-news.laohu8.com/highlight/detail?id=2629834641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629834641?lang=zh_cn&edition=full","pubTime":"2026-04-23 20:48","pubTimestamp":1776948501,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药(300158)04月22日在投资者关系平台上答复投资者关心的问题。投资者提问:2025年公司3年以上应收账款占应收账款比例达到27.78%,公司销售是真实的吗?为什么应收货款超过3年没收回?振东制药回复:尊敬的投资者您好!公司相关销售均基于真实业务背景,收入真实合规。公司已建立专项催收机制,持续推进回款,风险总体可控。感谢您的关注!以上内容为证券之星据公开信息整理,由AI算法生成(网信算备310104345710301240019号),不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042300058963.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0060","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629051971","title":"股市必读:振东制药年报 - 第四季度单季净利润同比增长76.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629051971","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629051971?lang=zh_cn&edition=full","pubTime":"2026-04-22 01:55","pubTimestamp":1776794112,"startTime":"0","endTime":"0","summary":"股本股东变化股东户数变动近日振东制药披露,截至2026年3月31日公司股东户数为5.15万户,较12月31日增加1315.0户,增幅为2.62%。归属于上市公司股东的净利润为-3.01亿元,同比减亏77.34%。2025年财务报告山西振东制药股份有限公司2025年度财务报告经中审华会计师事务所审计,出具标准无保留意见审计报告。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042200004908.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629720308","title":"图解振东制药年报:第四季度单季净利润同比增长76.52%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629720308","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629720308?lang=zh_cn&edition=full","pubTime":"2026-04-21 01:06","pubTimestamp":1776704807,"startTime":"0","endTime":"0","summary":"证券之星消息,振东制药2025年年报显示,当年度公司主营收入27.83亿元,同比下降6.33%;归母净利润-3.01亿元,同比上升77.34%;扣非净利润-3.23亿元,同比上升52.89%;其中2025年第四季度,公司单季度主营收入5.69亿元,同比下降18.98%;单季度归母净利润-3.21亿元,同比上升76.52%;单季度扣非净利润-3.24亿元,同比上升50.63%;负债率28.4%,投资收益1078.15万元,财务费用141.67万元,毛利率50.06%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042100002344.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628725900","title":"振东制药(300158.SZ)发布一季度业绩,由盈转亏至104.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628725900","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628725900?lang=zh_cn&edition=full","pubTime":"2026-04-20 21:08","pubTimestamp":1776690533,"startTime":"0","endTime":"0","summary":"智通财经APP讯,振东制药(300158.SZ)发布2026年第一季度报告,该公司营业收入为6.49亿元,同比减少13.97%。归属于上市公司股东的净亏损为104.59万元。归属于上市公司股东的扣除非经常性损益的净亏损为1111.24万元。基本每股亏损为0.0011元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430920.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0060","300158","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624684766","title":"振东制药(300158)披露为全资子公司提供担保进展公告,4月3日股价下跌4.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624684766","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624684766?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:08","pubTimestamp":1775225305,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘,振东制药报收于6.16元,较前一交易日下跌4.64%,最新总市值为61.13亿元。该股当日开盘6.3元,最高6.42元,最低6.15元,成交额达2.61亿元,换手率为4.22%。近日,山西振东制药股份有限公司披露《关于为全资子公司提供担保的进展公告》。被担保人泰盛制药注册资本39,500万元,主营业务为药品生产,公司持有其100%股权。截至公告日,公司实际对外担保余额为15,000万元,占最近一期经审计净资产的4.06%,无逾期担保及诉讼担保情形。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","300158","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2607044720","title":"振东制药(300158)披露第四期员工持股计划第一次持有人会议决议公告,1月30日股价下跌2.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2607044720","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607044720?lang=zh_cn&edition=full","pubTime":"2026-01-30 23:04","pubTimestamp":1769785457,"startTime":"0","endTime":"0","summary":"截至2026年1月30日收盘,振东制药报收于5.72元,较前一交易日下跌2.56%,最新总市值为56.76亿元。公司于2026年1月30日披露《第四期员工持股计划第一次持有人会议决议公告》。公告显示,山西振东制药股份有限公司于2026年1月29日召开第四期员工持股计划第一次持有人会议,会议应参与表决持有人368人,代表本期员工持股计划份额206,750,000份,占总额度的82.70%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026013000047940.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0239","BK0186","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606847827","title":"振东制药:1月26日高管雷振宏增持股份合计1600股","url":"https://stock-news.laohu8.com/highlight/detail?id=2606847827","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606847827?lang=zh_cn&edition=full","pubTime":"2026-01-27 21:01","pubTimestamp":1769518899,"startTime":"0","endTime":"0","summary":"证券之星消息,根据1月27日市场公开信息、上市公司公告及交易所披露数据整理,振东制药最新董监高及相关人员股份变动情况:2026年1月26日公司董事雷振宏共增持公司股份1600.0股,占公司总股本为0.0002%。振东制药近半年内的董监高及核心技术人员增减持详情如下:振东制药的高管列表及最新持股情况如下:融资融券数据显示该股近5日融资净流出3069.86万,融资余额减少;融券净流出6.02万,融券余额减少。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700039946.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","300158","BK0239","BK0186"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606636802","title":"股市必读:振东制药(300158)预计2025年全年归属净利润亏损2.2亿元至2.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2606636802","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606636802?lang=zh_cn&edition=full","pubTime":"2026-01-26 01:57","pubTimestamp":1769363829,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘,振东制药报收于6.2元,上涨2.65%,换手率3.23%,成交量32.07万手,成交额1.98亿元。振东制药发布业绩预告,预计2025年全年扣非后净利润亏损2.35亿元至2.95亿元。公司公告汇总2025年度业绩预告山西振东制药股份有限公司预计2025年度归属于上市公司股东的净利润亏损22,000万元至28,000万元,上年同期亏损132,856.39万元;扣除非经常性损益后的净利润亏损23,500万元至29,500万元,上年同期亏损68,633.99万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012600000848.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2605547747","title":"振东制药(300158.SZ)发预亏,预计2025年归母净亏损2.2亿元至2.8亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2605547747","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605547747?lang=zh_cn&edition=full","pubTime":"2026-01-23 20:39","pubTimestamp":1769171955,"startTime":"0","endTime":"0","summary":"智通财经APP讯,振东制药(300158.SZ)披露2025年度业绩预告,公司预计归属于上市公司股东的净亏损2.2亿元至2.8亿元;扣除非经营性损益后的净亏损2.35亿元至2.95亿元。更多港股重磅资讯,下载智通财经app更多港股及海外理财资讯,请点击www.zhitongcaijing.com(搜索“智通财经”);欲加入智通港股投资群,请加智通客服微信(ztcjkf)","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"振东制药(300158.SZ)发预亏,预计2025年归母净亏损2.2亿元至2.8亿元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK0239","BK0186","BK0060","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2600067874","title":"每周股票复盘:振东制药(300158)聘任王锐为新任总裁","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067874","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067874?lang=zh_cn&edition=full","pubTime":"2026-01-03 02:33","pubTimestamp":1767378791,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,振东制药报收于5.81元,较上周的5.94元下跌2.19%。本周,振东制药12月29日盘中最高价报5.96元。振东制药当前最新总市值57.65亿元,在中药板块市值排名39/67,在两市A股市值排名3013/5181。本周关注点公司公告汇总:振东制药聘任王锐先生为公司总裁,任期至第六届董事会届满。表决结果为9票同意、0票反对、0票弃权,会议由董事长李昆主持。王锐先生现任公司营销总裁,未持有公司股份,与控股股东无关联关系。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0060","BK0186","BK0239","300158"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2595228772","title":"振东制药(300158)披露副总裁、董事会秘书辞职暨聘任总裁公告,12月31日股价上涨0.35%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595228772","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595228772?lang=zh_cn&edition=full","pubTime":"2025-12-31 22:12","pubTimestamp":1767190341,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘,振东制药报收于5.81元,较前一交易日上涨0.35%,最新总市值为57.65亿元。公司近日发布公告称,山西振东制药股份有限公司董事会收到副总裁、董事会秘书王哲宇先生的书面辞职报告,其因工作岗位调动申请辞去职务,辞职后仍在公司担任其他职务。董事长李昆先生将代行董事会秘书职责,直至新任秘书聘任到位。同时,公司第六届董事会第十一次会议审议通过聘任王锐先生为公司总裁,任期至第六届董事会届满。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100044676.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300158","BK0186","BK0239","BK0060"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1780181228343,"stockEarnings":[{"period":"1week","weight":-0.0821},{"period":"1month","weight":-0.1237},{"period":"3month","weight":-0.1834},{"period":"6month","weight":-0.2581},{"period":"1year","weight":0.1228},{"period":"ytd","weight":-0.1343}],"compareEarnings":[{"period":"1week","weight":-0.0108},{"period":"1month","weight":-0.0095},{"period":"3month","weight":-0.0227},{"period":"6month","weight":0.0463},{"period":"1year","weight":0.2096},{"period":"ytd","weight":0.0251}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"山西振东制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"51492人(较上一季度增加2.62%)","perCapita":"19255股","listingDate":"2011-01-07","address":"山西省长治市上党区光明南路振东科技园","registeredCapital":"99230万元","survey":" 山西振东制药股份有限公司的主营业务是肿瘤、皮科、消化、泌尿、心脑等仿制药、创新药的研发、生产、销售,以及种子种苗抚育、种植、加工、仓储、饮片于一体的中药材全产业链。公司的主要产品是复方苦参注射液、米诺地尔搽剂、生白颗粒、舒血宁注射液、西黄丸、独一味颗粒、复方胰酶散、大山楂丸。公司荣获“全国先进基层党组织”“全国脱贫攻坚先进集体”两个荣誉称号,荣获“第七届百姓安全用药”放心药奖、“山西省著名商标”等荣誉。","listedPrice":38.8},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.3","shortVersion":"4.42.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"振东制药,300158,振东制药股票,振东制药股票老虎,振东制药股票老虎国际,振东制药行情,振东制药股票行情,振东制药股价,振东制药股市,振东制药股票价格,振东制药股票交易,振东制药股票购买,振东制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"振东制药(300158)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供振东制药(300158)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}